MAP2K7 and neoplasm: Sorafenib exhibits a dual mechanism of action by inhibiting VEGFRs and PDGFR signaling and thus inhibiting the RAF/MEK/extracellular signal-regulated kinase (ERK) pathway to reduce tumor angiogenesis and to induce tumor cell apoptosis (Ramakrishnan et al., 2010).